Peptide receptor radionuclide therapy for neuroendocrine tumours: Standardized and randomized, or personalized?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 2, 2014, Pages 211-213

  Hofman, Michael S ^a,b   Hicks, Rodney J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; CAPECITABINE; CREATININE; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GADOLINIUM TETRAAZACYCLODODECANTECANETETRAACETIC ACID OCTREOTATE; INDIUM 111; IODINE 131; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; HUMAN; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NOTE; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THYROID CANCER;

FEMALE; HUMANS; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOPHARMACEUTICALS;

EID: 84897069621     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2621-6     Document Type: Note

References (20)

1. Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010;10 Spec no A:S83-91. doi:10.1102/1470-7330.2010.9007.
2. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-63. doi:10.1200/JCO.2009.22.8510.
3. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-23. doi:10.1056/NEJMoa1009290.
4. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-13. doi:10. 1056/NEJMoa1003825.
5. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268-75. doi:10.1002/cncr.25425.
6. Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, et al. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2559-8.
7. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer. 2009;9:388. doi:10.1186/1471-2407-9-388.
8. Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302-11. doi:10.1007/s00259-010-1631-x.
9. Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, et al. Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide. Theranostics. 2012;2:472-80. doi:10. 7150/thno.3739.
10. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metasta-sized neuroendocrine cancers. J Clin Oncol. 2011;29:2416-23. doi: 10.1200/JCO.2010.33.7873.
11. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med. 1993;20:716-31.
12. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-62. doi: 10.1200/JCO.2005.08.066.
13. Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787-94. doi:10.1093/annonc/mdp372.
14. Horsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Krause BJ, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res. 2013;194:457-65. doi:10.1007/978-3-642-27994-2-25.
15. Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, et al. Treatment with tandem [(90)Y] DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54: 84-91.
16. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). http://www.cebm.net/?o=1025. 2009.
17. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327:1459-61. doi:10.1136/bmj.327. 7429.1459.
18. Hofman MS, Hicks RJ. Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med. 2012;14:71-81.
19. Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50-6. doi:10.1007/s00259-011-1937-3.
20. Hubble D, Kong G, Michael M, Johnson V, Ramdave S, Hicks RJ. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide. Eur J Nucl Med Mol Imaging. 2010;37:1869-75. doi:10.1007/s00259-010-1483-4.